2022

Featured HTB November/December 2022 (16 December 2022)

16 December 2022. Related: Editorial.

Supporting Ukraine

1 December 2022. Related: Editorial.

In memory: Giulio Maria CorbellI and Chris Sandford

1 December 2022. Related: In memory.

Latest statistics on HIV in the UK: data for 2021

1 December 2022. Related: Special reports, HIV prevention and transmission.

Glasgow HIV Congress 2022

1 December 2022. Related: Conference reports.

Glasgow 2022: Better re-suppression after viral rebound with DTG-based ART compared to EFV- or PI-based regimens

1 December 2022. Related: Conference reports, Treatment strategies.

Glasgow 2022: Vertical transmission rate below 0.3% among women living with HIV in the UK

1 December 2022. Related: Conference reports, Pregnancy.

Glasgow 2022: Impact of islatravir on lymphocyte counts in a dose-ranging study: a post-hoc analysis

1 December 2022. Related: Conference reports, Antiretrovirals.

Glasgow 2022: Islatravir studies to use 0.25 mg daily dose to overcome risk of reducing CD4 and total lymphocytes

1 December 2022. Related: Conference reports, Antiretrovirals.

Glasgow 2022: Fostemsavir 240 week results from BRIGHTE study

1 December 2022. Related: Conference reports, Antiretrovirals.

Glasgow 2022: Fostemsavir: QT prolongation and drug-drug interactions

1 December 2022. Related: Conference reports, Antiretrovirals.

Glasgow 2022: Mpox updates on epidemiology, treatment and prevention

1 December 2022. Related: Conference reports, Monkeypox.

24th International AIDS Conference (AIDS 2022): Final report

1 December 2022. Related: Conference reports.

IAS 2022: Metabolic complications of newer HIV drugs in older people

1 December 2022. Related: Conference reports, Lipodystrophy and metabolic complications.

Cabotegravir-LA submitted to EMA for use as PrEP in Europe

1 December 2022. Related: HIV prevention and transmission.

CHAI 2022 report on global access to ART

1 December 2022. Related: Treatment access.

Early HIV diagnosis and treatment are important for better long-term health

1 December 2022. Related: Antiretrovirals.

EU recommends approval of dispersible abacavir/lamivudine/dolutegravir FDC for children weighing 14 to >25 kg

1 December 2022. Related: Antiretrovirals, Paediatric care.

BHIVA 2022 ART guidelines: online with non-technical summary

1 December 2022. Related: Guidelines.

National HIV prescribing for England 2022: algorithms and policies

1 December 2022. Related: Guidelines.

EACS Guidelines update (2022)

1 December 2022. Related: Guidelines.

IAS–USA Guidelines on HIV Treatment and Prevention (2022)

1 December 2022. Related: Guidelines.

Training webinar: 2nd HIV from A to Z

1 December 2022. Related: On the web, Future meetings.

Future meetings and webinars 2023

1 December 2022. Related: Future meetings.

HTB: no. 11/12 (November/December 2022) PDF download

1 December 2022. Related: PDFs.

Featured HTB October 2022 (3 October 2022)

3 October 2022. Related: Editorial.

Monkeypox into Autumn: still no emergency funding, vaccine efficacy and UK declines further vaccines

3 October 2022. Related: Special reports, Monkeypox.

BHIVA General Medicine Course 2022

3 October 2022. Related: Future meetings.

14th International Workshop on HIV & Pediatrics

3 October 2022. Related: Conference reports.

Switch study for people with insomnia using dolutegravir: still enrolling

3 October 2022. Related: Research studies.

First paediatric pharmacokinetic data of dolutegravir in combination with a TAF-based NRTI backbone

3 October 2022. Related: Conference reports, Paediatric care.

24th International AIDS Conference (AIDS 2022): further reports

3 October 2022. Related: Conference reports.

AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3

3 October 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.

AIDS 2022: Gender-affirming hormones, weight gain and ART

3 October 2022. Related: Conference reports, PK and drug interactions, Side effects.

Islatravir update: treatment studies to use a lower dose but PrEP research discontinued in favour of MK-8537

3 October 2022. Related: Antiretrovirals.

Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence

3 October 2022. Related: Antiretrovirals, Resistance.

Tecovirimat treatment for monkeypox in the UK: importance of the PLATINUM study

3 October 2022. Related: Monkeypox.

Levels of monkeypox viral load in different body sites supports highest risk from body contact

3 October 2022. Related: Monkeypox.

Severe complication of monkeypox reported to the US CDC: risks associated with HIV and other causes of immunosuppression

3 October 2022. Related: Monkeypox.

New reports on MPX vaccine efficacy suggest protection but cases reported after two shots

3 October 2022. Related: Monkeypox.

Other monkeypox studies of interest

3 October 2022. Related: Monkeypox.

BHIVA, BASHH and other professional organisations publish open letters on the refusal by the UK government to acknowledge monkeypox crisis

3 October 2022. Related: Monkeypox.

Reduced HAND prevalence in large cross-sectional cohort study

3 October 2022. Related: Coinfections and complications.

Update to IAS-USA drug resistance tables

3 October 2022. Related: Resistance.

HTB: no. 10 (3 October 2022) PDF download

3 October 2022. Related: PDFs.

HTB: no. 9 (3 September 2022) PDF download

1 September 2022. Related: PDFs.

Featured HTB September 2022 (1 September 2022)

1 September 2022. Related: Editorial.

Featured Update on monkeypox in the UK: reduced cases, vaccine access, transmission and treatment…

1 September 2022. Related: Special reports, Monkeypox.

24th International AIDS Conference (AIDS 2022)

1 September 2022. Related: Conference reports.

Dolutegravir no longer linked to higher risk of neural tube defects: latest update from the Tsepamo study

1 September 2022. Related: Conference reports, Pregnancy.

Weight gain with dolutegravir and TAF in ADVANCE study continues out to week 192

1 September 2022. Related: Conference reports, Women's health.

VRC01 added to early ART in infants did not reduce viral reservoir

1 September 2022. Related: Conference reports, Paediatric care.

Using PrEP during pregnancy is safe for children

1 September 2022. Related: Conference reports, Pregnancy, Paediatric care.

Long-acting CAB/RPV injections have a similar weight and lipid profile to dolutegravir-based oral ART

1 September 2022. Related: Conference reports.

Montreal’s response to monkeypox: rapid vaccine rollout, 39 breakthrough infections

1 September 2022. Related: Conference reports, Monkeypox.

Summary of 620 cases of monkeypox seen at three London clinics

1 September 2022. Related: Conference reports, Monkeypox.

Advances in HIV cure-related research: IAS workshop now online

1 September 2022. Related: Conference reports.